T1	Participants 459 521	One hundred seventy-six patients with necrotizing pancreatitis
T2	Participants 1115 1318	patients treated with meropenem and those treated with imipenem in terms of incidence of pancreatic infection (11.4% versus 13.6%) and extrapancreatic infections (21.6% versus 23.9%) and clinical outcome
